We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

ThromboGenics and BioInvent Start Phase II Trial of TB-402 for Deep Vein Thrombosis Prophylaxis

News   Feb 24, 2009

 
ThromboGenics and BioInvent Start Phase II Trial of TB-402 for Deep Vein Thrombosis Prophylaxis
 
 
 

RELATED ARTICLES

“Smart Drug” Shows Promise for Metastatic Triple-Negative Breast Cancer

News

A new "smart drug" has shown promise for women with metastatic triple-negative breast cancer, based on data from a clinical trial at NewYork-Presbyterian/Columbia's Herbert Irving Comprehensive Cancer Center and other centers.

READ MORE

Rubicon Alters Autophagy in Animals During Aging

News

Rubicon is a protein factor that suppresses autophagy by controlling a specific step in this pathway. This study found that Rubicon expression levels increased in an age-related manner in worm, fly, and mouse tissues.

READ MORE

Drug Combo Could Become New Standard Treatment for Advanced Kidney Cancer

News

A combination of two drugs – one of them an immunotherapy agent – could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a Phase 3 clinical trial.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE